TY - JOUR
T1 - Anticancer evidence for zoledronic acid across the cancer continuum
AU - Costa, Luis
AU - Harper, Peter
AU - Coleman, Robert E.
AU - Lipton, Allan
N1 - Funding Information:
Dr. Luis Costa has received honoraria and consulting fees from Novartis, Amgen, and Roche, and has received research funding from Novartis and Amgen. Dr. Peter Harper has received honoraria from Eli Lilly, Roche, Pfizer, GSK, and Novartis. Dr. Robert Coleman has received honoraria and consulting fees from Novartis, Amgen, Roche, AstraZeneca, and Pfizer; has received research funding from Novartis; and has previously given expert testimony on behalf of Novartis. Dr. Lipton has served as a consultant for Amgen and Novartis; has received honoraria from Amgen, Novartis, and Genentech; has received research funding from Novartis, Monogram Biosciences, and Oncogene Sciences; and has given expert testimony for Novartis.
PY - 2011/2
Y1 - 2011/2
N2 - Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.
AB - Emerging evidence from clinical trials with zoledronic acid (ZOL) suggests that ZOL may have anticancer activity in a variety of cancer types. Retrospective studies and subset analyses as well as prospectively designed clinical trials have demonstrated that ZOL has survival benefits in patients with advanced cancers. Several studies have shown that ZOL improves disease-free survival, reduces the persistence of circulating and disseminated tumor cells, which are known to be predictive of disease recurrence, and decreases residual invasive tumor size in patients with early breast cancer. These data suggest that, in addition to providing skeletal-related event (SRE) benefits, ZOL also may potentially provide clinically meaningful benefits through anticancer activity. This article reviews the breadth of evidence supporting the anticancer activity of ZOL across the treatment continuum in patients with cancer.
UR - http://www.scopus.com/inward/record.url?scp=79951842507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951842507&partnerID=8YFLogxK
U2 - 10.1016/S1040-8428(11)70006-3
DO - 10.1016/S1040-8428(11)70006-3
M3 - Review article
C2 - 21353179
AN - SCOPUS:79951842507
SN - 1040-8428
VL - 77
SP - S31-S37
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - SUPPL.1
ER -